Price History
Paint companies in India, including Grasim, Berger, and Indigo, are grappling with potential demand issues due to recent price increases caused by inflation and crude-linked costs. The firms anticipate testing the limits of demand elasticity (Grasim), and both Indigo and Berger warn about increased competitive pressure and margin squeeze.
Vodafone Idea experiences a significant 46% surge over the past month due to recent capital infusions, while Grasim reaches a new high at ₹3,198.10, boosted by impressive Q4FY26 revenue and EBITDA figures.
Grasim shares have seen a significant rise, sparking interest among investors. Market analysts are now closely watching potential support levels for the stock.
Grasim Industries posted a significant 2.5 times year-on-year increase in Q4 earnings before interest, taxes, depreciation, and amortization (EBITDA), reaching ₹540 crore. The company also experienced a 210 basis point year-on-year improvement in margins, although they remained steady quarter-over-quarter. Analysts continue to express optimism about the firm's prospects.
Grasim Industries has reached a 52-week high, joining seven other leading companies that have seen a notable increase of up to 25% over the past month.
Grasim Industries has been moved by Nuvama to a 'Buy' recommendation, with an increased target price of INR 3,546 – a rise from the previous target of INR 3,336. This change suggests positive expectations for Grasim's future performance.
Grasim has reported a significant decrease in quarterly losses, with the deficit shrinking from ₹288 crore last year to ₹163 crore this year. The company's revenue also saw an increase, reaching ₹11,774 crore. EBITDA improved significantly, growing from ₹221 crore to ₹541 crore, resulting in an increased margin of 4.5%. Grasim has also announced a dividend of ₹10 per share for its shareholders.
The Nifty index has surpassed 23,650 today, with key contributors including Grasim, Indigo, and Apollo Hospitals. Notable gains are being observed in these stocks during the afternoon trading session.
Grasim plans to achieve EBITDA breakeven by the end of FY27, emphasizing growth and market expansion. UltraTech Cement aims to increase its production capacity to over 240 MTPA by March 2028, as per their recent conference call update.
Today, 10 notable companies such as Grasim, Ola Electric, Bosch, and others will release their Q4 results, with a focus on revenue, profit margins, and future outlook by investors. These companies span sectors including healthcare, electric vehicles, infrastructure, and appliances, which can significantly impact the market's overall sentiment.
Grasim shares rose by 4.7%, reaching a 52-week high of ₹3,110 on the NSE, following strong Q4 FY26 results that showed a 15% year-on-year revenue growth. The bullish sentiment continues as brokerages like MOFSL and Choice reiterate their 'Buy' recommendations, recognizing the company's growth in sectors such as paints, B2B e-commerce, and chemicals, along with margin expansion.
Grasim Industries reached a new record high of Rs 3,098 on May 21, 2026, demonstrating a significant 3.4% increase that surpassed both its sector and the overall market performance.
Grasim surpassed expectations in Q4 with Cellulosic Fibre and Chemicals earning ₹588 crores and ₹304 crores respectively. Birla Opus experienced a 52% year-on-year growth, but B2B e-commerce faced an EBITDA loss of ₹302 Cr, anticipating profitability by FY27.
Grasim announces a commitment to re-invest all earnings from sales and EBITDA towards expansion projects, focusing on growth opportunities. The company intends to maintain more than half ownership in UltraTech and Aditya Birla Capital for the long term.
Despite recording a net loss of INR 163 crore, Grasim Industries has decided to distribute dividends, indicating a resilient financial strategy.
Aditya Birla Capital plans to release approximately INR 2,880 crores in shares to Grasim Industries, further strengthening their financial ties. This share issue could potentially facilitate growth and strategic opportunities for both companies.
Grasim surpasses expectations in Q4, driven by impressive VSF performance, signaling continued growth potential. Mankind Pharma exhibits strong domestic expansion, while Jubilant Food faces margin challenges. Apollo Hospitals receives mixed reviews due to valuation concerns, but a positive outlook following AB Capital's equity raise.
Grasim Industries plans to reach INR10,000 crore in revenue for its division Birla Opus by the financial year 2028-29, starting from the base year of 2025-26. The goal is to secure the No. 2 spot in the decorative paints market with a projected high double-digit growth rate by FY27.
According to the latest ET NOW poll, Grasim Industries' Q4 earnings fell short of expectations as per the discussion under the #Q4WithETNOW. Investors may want to keep a close eye on any potential updates from the company.
Grasim Industries has given the green light for a Rs 2,880 crore share issue, which could potentially influence their stock market position.
Morgan Stanley maintains a positive outlook for Grasim, increasing its target price to ₹3,900, suggesting optimism about the company's future growth prospects.
Grasim Industries reported a reduced Q4 loss of INR 1.64 billion, largely due to an improvement in its core business. The company's standalone EBITDA surged by 47% to INR 6.59 billion. The growth was primarily driven by strong performances from UltraTech Cement and financial services sectors, contributing significantly to the group's overall revenue.
Grasim Industries, following its Q4 results announcement, experienced a significant rise of approximately 4%, placing it at the forefront as the top gainer in the Nifty index today.
Grasim Industries reports a 18% increase in annual revenue for FY26, reaching INR 1,75,431 Cr, with EBITDA climbing 29%. Particularly noteworthy is the paint division's impressive 52% growth year-over-year. This success can be attributed to expanded cement capacity exceeding 200 mtpa and a 32% jump in lending portfolio.
The Nifty index is finding resistance at its 50-day moving average, with the IT sector showing a 6% growth. Pivotal results from companies like Apollo Hospitals, Grasim, BEL, BPCL, and IRB Infra are expected to shape market direction.
Grasim Industries is expected to reveal its Q4 earnings soon, as per AwaazEarnings analysis. Key takeaways from the discussion include potential growth indicators and profitability trends. Stay tuned for the official announcement.
Grasim's projected earnings and profit growth have been highlighted by analyst Pooja, with updates provided by Anil Singhvi in the latest financial analysis on Zee Business.
Apollo Hospitals anticipates a 19% increase in Q2 profits with potential revenue growth of 17%. Grasim's results are also due, while Jubilant Foods, Samvardhana Motherson, and two other futures companies await their turn to announce their financial performance.
Grasim Industries' Q4 earnings before interest, taxes, depreciation, and amortization (EBITDA) significantly increased by approximately 150% year-over-year to reach ₹5.4 billion, with the EBITDA margin also doubling to 4.6%. This promising growth indicates a strong finish for Grasim in Q4.
Companies like Grasim, Apollo Hospitals, and Bosch are set to release their Q4 FY26 financial results today, joining a total of 123 companies disclosing their earnings for the quarter.
Grasim increased prices in Q4 FY26 and Q1 FY27 to maintain competitiveness and counterbalance rising input costs, narrowing the gap with competitors.
Grasim Industries has announced its intention to purchase a 26% stake in Ampin C I Power, marking a push towards hybrid renewable energy solutions. This strategic investment is aimed at meeting both green energy requirements and the need for captive power, in line with regulatory demands.
Today, Lenskart, Grasim, Apollo Hospitals, Jubilant Foodworks, BEL, BPCL, and Zee Entertainment will reveal their Q4 earnings. Additionally, IRB Infra, Whirlpool India, Hindalco, and Mankind Pharma are also releasing results. Notably, mixed outcomes have been observed in some companies, particularly BPCL.
The benchmark GIFT Nifty index has dropped by approximately 165 points to around 23,450, aligning with a general decline in US markets. Meanwhile, Apollo Hospitals and Grasim are set to announce their results today, while banks prepare for increased disclosure requirements.
Grasim Industries successfully repaid a sum of ₹250 crore in commercial papers on May 15, 2026. The full repayment was completed, eliminating any remaining debt.
Grasim stands to gain a significant Rs 3,970 crore dividend from UltraTech, bolstering its resources for future growth. Analysts at Jefferies anticipate a potential 15% increase in value, suggesting funds could be utilized for expanding the paints business, strengthening B2B operations, and reducing debt.
Grasim Industries just completed a significant block trade on the NSE, worth approximately INR 18 crores for over 60,000 shares, with each share being sold at INR 2,957.
Jefferies has kept a Buy rating on Grasim with a target price of ₹3440, largely due to an expected ₹39.7bn dividend from UltraTech Cement. This dividend inflow could boost Grasim's financial flexibility for growth initiatives, debt reduction, and enhanced shareholder rewards, potentially lessening the discount associated with being a holding company.
Grasim Industries has scheduled a board meeting on the 20th of May, 2026. Expect potential strategic decisions or updates from this gathering.